OTC Markets EXMKT - Delayed Quote USD

Claritas Pharmaceuticals, Inc. (CLAZF)

0.0001
0.0000
(0.00%)
At close: May 7 at 4:00:00 PM EDT
Loading Chart for CLAZF
  • Previous Close 0.0000
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.0001
  • Volume 250
  • Avg. Volume 0
  • Market Cap (intraday) 664,660
  • Beta (5Y Monthly) 33.74
  • PE Ratio (TTM) 0.00
  • EPS (TTM) 0.9000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CLAZF

View More

Performance Overview: CLAZF

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CLAZF
0.00%
S&P 500 (^GSPC)
3.77%

1-Year Return

CLAZF
900.00%
S&P 500 (^GSPC)
8.55%

3-Year Return

CLAZF
99.83%
S&P 500 (^GSPC)
41.81%

5-Year Return

CLAZF
99.96%
S&P 500 (^GSPC)
93.18%

Compare To: CLAZF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CLAZF

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    2.77%

  • Return on Equity (ttm)

    65.09%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    1.8M

  • Diluted EPS (ttm)

    0.9000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2k

  • Total Debt/Equity (mrq)

    16.40%

  • Levered Free Cash Flow (ttm)

    -10.71M

Research Analysis: CLAZF

View More

Company Insights: CLAZF

Research Reports: CLAZF

View More

People Also Watch